

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**上海復旦張江生物醫藥股份有限公司**

**Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code:1349)**

## **VOLUNTARY ANNOUNCEMENT**

### **DETERMINING THE ISSUE PRICE RANGE OF THE ISSUE OF A SHARES**

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\* (the “**Company**”) on a voluntary basis.

References are made to the announcements of the Company dated 8 March 2019, 12 March 2019, 26 April 2019, 7 May 2019, 13 May 2019, 21 June 2019, 31 July 2019, 29 August 2019, 2 September 2019, 29 September 2019, 10 October 2019, 20 October 2019, 27 October 2019, 31 October 2019, 19 March 2020, 20 March 2020, 25 March 2020, 3 April 2020, 13 April 2020, 14 May 2020, 18 May 2020 and 29 May 2020 and the circulars of the Company dated 12 March 2019, 4 April 2019, 6 June 2019 and 4 March 2020 containing, among other things, related matters of the proposed initial public offering of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the “**Shanghai Stock Exchange**”) by the Company (the “**Issue of A Shares**”). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circulars.

The board of Directors (the “**Board**”) of the Company announces that, after the completion of the preliminary price consultation with the price consultation

participants on 3 June 2020 and excluding the highest quoted portion of the total volume of proposed subscriptions, the Company and the joint lead underwriters determined the offer price range to be from RMB8.65 per share to RMB8.95 per share through negotiation, taking into account of the Company's fundamentals, industry conditions and the price earning ratios of comparable companies. The difference between the upper and lower limits of the offer price range does not exceed 20% of the lower limit of the offer price range.

The Company will determine the offer price of the Issue of A Shares by cumulative tender price consultation with the price consultation participants that provide a valid price quote within the offer price range on 8 June 2020. Once the final size and offer price of the Issue of A Shares are determined, the Company will issue a separate announcement.

For details in relation to the relevant terms and offer price range of the Issue of A Shares, please refer to the full text of "Announcement in Relation to the Initial Public Offering of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and Listing on the Sci-Tech Innovation Board" and "Announcement in Relation to the Initial Public Offering of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and Offer Price Range of the Listing on the Sci-Tech Innovation Board" of the Company published in Chinese only on the website of Shanghai Stock Exchange ([www.sse.com.cn](http://www.sse.com.cn)) on 5 June 2020.

**This announcement is for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company. The Company will inform the Shareholders and potential investors of the further development of the Issue of A Shares in accordance with the Listing Rules and applicable laws and regulations.**

By order of the Board  
**Wang Hai Bo**  
*Chairman*

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

5 June 2020

*\* For identification purpose only*